Skip to main content

How long does Velcade stay in your body?

Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on Oct 25, 2024.

Official Answer by Drugs.com

You could expect Velcade to stay in your system ranging from 9 days (220 hours) to 44 days (1061 hours) depending on which dose you receive.

The elimination half life is the time it takes for your body to reduce the plasma levels of the drug by one-half (50%). It usually takes around 5.5 x the half-live for a drug to be completely eliminated from your system. The elimination half life of Velcade (bortezomib) ranges from 40 hours to 193 hours after the 1 mg per m2 dose and 76 to 108 hours after the 1.3 mg per m2 dose.

Velcade (bortezomib) shows a biphasic elimination profile, which means is has a rapid distribution and uptake in your body, followed by a longer elimination.

Factors that can affect the elimination time of a medicine from your body include:

Velcade (bortezomib) is an anticancer medicine given to adults to treat multiple myeloma (a cancer of plasma cells) or mantle cell lymphoma (a cancer of the lymph nodes). It is given into your vein (intravenous) or as a subcutaneous (under the skin) injection. It interferes with cancer cell growth and helps to keep it from spreading. It is given with other medicines during your treatment cycles.

This is not all the information you need to know about Velcade (bortezomib) for safe and effective use and does not take the place of talking to your doctor about your treatment. Review the full Velcade information and discuss this medicine and any questions you have with your doctor or other health care provider.

Related questions

References
  • Velcade (bortezomib) prescribing information. Revised 10/2021. Takeda Pharmaceuticals. Accessed Nov. 4, 2021 at https://www.velcade.com/files/pdfs/VELCADE_PRESCRIBING_INFORMATION.pdf
  • Ogawa Y, Tobinai K, Ogura M, et al. Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma. Cancer Sci. 2008 Jan;99(1):140-4. doi: 10.1111/j.1349-7006.2007.00638.x.
  • Schwartz R, Davidson T. Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Williston Park). 2004 Dec;18(14 Suppl 11):14-21. PMID: 15688598.

Read next

What are the best treatments for Multiple Myeloma?

Multiple myeloma is a cancer of plasma cells, which are white blood cells responsible for producing antibodies. While not yet curable, advancements in therapy have transformed it into a manageable condition with treatments that can achieve long-term disease control and improved quality of life. Initial treatment usually involves multi-drug combinations, such as bortezomib (a proteasome inhibitor), lenalidomide (an immunomodulatory drug), and dexamethasone (a steroid).

Continue reading

How Does Chemotherapy Work for Multiple Myeloma?

Chemotherapy remains a cornerstone in managing multiple myeloma, a cancer of plasma cells in the bone marrow. While newer therapies like immunomodulators and proteasome inhibitors have expanded treatment options, chemotherapy continues to play a vital role—particularly when combined with other approaches.

Continue reading

Can Darzalex cure Multiple Myeloma?

Although Darzalex cannot cure multiple myeloma it can improve the quality and length of life in most people. There are two types of Darzalex: Darzalex (daratumumab) and Darzalex Faspro (daratumumab and hyaluronidase). Continue reading

See also:

Related medical questions

Drug information

Related support groups